Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03139604
Study type Interventional
Source Incyte Corporation
Contact
Status Completed
Phase Phase 3
Start date July 19, 2017
Completion date July 13, 2020

See also
  Status Clinical Trial Phase
Completed NCT03112603 - A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Phase 3
Completed NCT02953678 - A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) Phase 2
Completed NCT02614612 - Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD Phase 1
Approved for marketing NCT03147742 - An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Approved for marketing NCT05722912 - Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD